Literature DB >> 17190853

The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study.

Paula D James1, Colleen Notley, Carol Hegadorn, Jayne Leggo, Angie Tuttle, Shawn Tinlin, Christine Brown, Chandler Andrews, Andrea Labelle, Yvette Chirinian, Lee O'Brien, Maha Othman, Georges Rivard, Dilys Rapson, Christine Hough, David Lillicrap.   

Abstract

In order to evaluate the changes within the VWF gene that might contribute to the pathogenesis of type 1 von Willebrand disease (VWD), a large multicenter Canadian study was undertaken. We present data from the sequence analysis of the VWF gene in 123 type 1 VWD index cases and their families. We have identified putative mutations within the VWF gene in 63% (n = 78) of index cases, leaving 37% (n = 45) with no identified changes. These changes comprise 50 different putative mutations: 31 (62%) missense mutations, 8 (16%) changes involving the VWF transcriptional regulatory region, 5 (10%) small deletions/insertions, 5 (10%) splicing consensus sequence mutations, and 1 nonsense mutation. Twenty-one of the index cases had more than one putative VWF mutation identified. We were somewhat more likely to identify putative mutations in cases with lower VWF levels, and the contribution of other factors, such as ABO blood group, seems more important in milder cases. Taken as a whole, our data support a complex spectrum of molecular pathology resulting in type 1 VWD. In more severe cases, genetic changes are common within the VWF gene and are highly penetrant. In milder cases, the genetic determinants are more complex and involve factors outside of the VWF gene.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17190853     DOI: 10.1182/blood-2006-05-021105.

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  91 in total

1.  VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population.

Authors:  Daniel B Bellissimo; Pamela A Christopherson; Veronica H Flood; Joan Cox Gill; Kenneth D Friedman; Sandra L Haberichter; Amy D Shapiro; Thomas C Abshire; Cindy Leissinger; W Keith Hoots; Jeanne M Lusher; Margaret V Ragni; Robert R Montgomery
Journal:  Blood       Date:  2011-12-23       Impact factor: 22.113

Review 2.  Von Willebrand disease in the United States: a perspective from Wisconsin.

Authors:  Veronica H Flood; Joan Cox Gill; Kenneth D Friedman; Daniel B Bellissimo; Sandra L Haberichter; Robert R Montgomery
Journal:  Semin Thromb Hemost       Date:  2011-11-18       Impact factor: 4.180

3.  Critical von Willebrand factor A1 domain residues influence type VI collagen binding.

Authors:  V H Flood; J C Gill; P A Christopherson; D B Bellissimo; K D Friedman; S L Haberichter; S R Lentz; R R Montgomery
Journal:  J Thromb Haemost       Date:  2012-07       Impact factor: 5.824

4.  Polymorphic variation within the VWF gene contributes to the failure to detect mutations in patients historically diagnosed with type 1 von Willebrand disease from the MCMDM-1VWD cohort.

Authors:  Daniel J Hampshire; George J Burghel; Jenny Goudemand; Laura C S Bouvet; Jeroen C J Eikenboom; Reinhard Schneppenheim; Ulrich Budde; Ian R Peake; Anne C Goodeve
Journal:  Haematologica       Date:  2010-09-17       Impact factor: 9.941

5.  Genetic variation associated with plasma von Willebrand factor levels and the risk of incident venous thrombosis.

Authors:  Nicholas L Smith; Kenneth M Rice; Edwin G Bovill; Mary Cushman; Joshua C Bis; Barbara McKnight; Thomas Lumley; Nicole L Glazer; Astrid van Hylckama Vlieg; Weihong Tang; Abbas Dehghan; David P Strachan; Christopher J O'Donnell; Jerome I Rotter; Susan R Heckbert; Bruce M Psaty; Frits R Rosendaal
Journal:  Blood       Date:  2010-12-16       Impact factor: 22.113

6.  Clinical utility gene card for: von Willebrand disease.

Authors:  Anthony M Cumming; Stephen Keeney; P Vincent Jenkins; Michael J Nash; James S O'Donnell
Journal:  Eur J Hum Genet       Date:  2011-01-05       Impact factor: 4.246

7.  Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States.

Authors:  Veronica H Flood; Pamela A Christopherson; Joan Cox Gill; Kenneth D Friedman; Sandra L Haberichter; Daniel B Bellissimo; Rupa A Udani; Mahua Dasgupta; Raymond G Hoffmann; Margaret V Ragni; Amy D Shapiro; Jeanne M Lusher; Steven R Lentz; Thomas C Abshire; Cindy Leissinger; W Keith Hoots; Marilyn J Manco-Johnson; Ralph A Gruppo; Lisa N Boggio; Kate T Montgomery; Anne C Goodeve; Paula D James; David Lillicrap; Ian R Peake; Robert R Montgomery
Journal:  Blood       Date:  2016-02-09       Impact factor: 22.113

8.  Clinical and laboratory versus molecular markers for a correct classification of von Willebrand disease.

Authors:  Augusto B Federici; Maria T Canciani
Journal:  Haematologica       Date:  2009-05       Impact factor: 9.941

9.  Translational medicine advances in von Willebrand disease.

Authors:  D Lillicrap
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

10.  Third Åland islands conference on von Willebrand disease, 26-28 September 2012: meeting report.

Authors:  E Berntorp; B Fuchs; M Makris; R Montgomery; V Flood; J S O'Donnell; A B Federici; D Lillicrap; P James; U Budde; M Morfini; P Petrini; S Austin; C Kannicht; V Jiménez-Yuste; C Lee
Journal:  Haemophilia       Date:  2013-03       Impact factor: 4.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.